Proceeds from the Alexandria Real Estate Equities-backed series B round will advance the company's development of progenitor cell-related medicines for hearing loss.

US-based drug developer Frequency Therapeutics closed a $42m series B round on Monday that included the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities. Alexandria Venture Investments was joined by venture capital firm Taiwania Capital, which led the round, and Axil Capital, a VC fund spun out of investment…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.